Copyright © 2021. Inderes Oyj. All rights reserved.

TR-1: Standard form for notification of major holdings

[][][][][][][][]
NOTIFICATION OF
MAJOR HOLDINGS
(to
be sent to the
relevant issuer
and
to the FCA in
Microsoft Word
format
if possible)[i]

1a. Identity of Faron Pharmaceuticals
the issuer or the Ltd
underlying issuer
of existing
shares
to which voting
rights are
attached[ii]:[ ]
1b. Please
indicate if the
issuer is
a non-UK issuer 
(please mark with
an "X" if
appropriate)
Non-UK issuer X
2. Reason for the
notification
(please mark the
appropriate box
or
boxes with an
"X")
An acquisition or x
disposal of
voting
rights
An acquisition or
disposal of
financial
instruments
An event changing
the breakdown of
voting rights
Other (please
specify)[iii]:
(Decrease of
holding due to
issuance
of new shares)
3. Details of
person subject to
the
notification
obligation[iv]
Name Timo Syrjälä
City and country
of registered
office (if
applicable)
4. Full name of
shareholder(s)
(if
different from
3.)[v]
Name
City and country
of registered
office (if
applicable)
5. Date on which  7.5.2021
the threshold was
crossed or
reached[vi]:
6. Date on which 10.5.2021
issuer notified
(DD/MM/YYYY):
7. Total
positions of
person(s)
subject to the
notification
obligation
% of voting % of voting Total of both Total
rights rights in % (8.A + number of
attached to through 8.B) voting
shares financial rights of
(total instruments issuer[vii]
of 8. A) (total of
8.B 1 + 8.B
2)
Resulting  14.09% 14.09%  50,457,874
situation on the
date on
which threshold
was crossed or
reached
Position of 13.57% 13.57%
previous
notification
(if applicable)

[][][][][][][]
8. Notified
details of the
resulting
situation on
the date on
which the
threshold was
crossed or
reached[viii]
A: Voting
rights
attached to
shares
Class/type of Number of % of voting rights
sharesISIN voting
code (if rights[ix]
possible)
Direct(Art 9 Indirect(Art Direct(Art 9 of Indirect(Art 10 of
of Directive 10 of Directive Directive 2004/109/EC)
2004/109/EC) Directive 2004/109/EC) (DTR5.2.1)
(DTR5.1) 2004/109/EC) (DTR5.1)
(DTR5.2.1)
FI4000153309 2,561,402 4,550,285 5.08% 9.02%

SUBTOTAL 8. A 7,111,687 14.09%

B 1: Financial
Instruments
according to
Art. 13(1)(a)
of Directive
2004/109/EC
(DTR5.3.1.1
(a))
Type of Expiration Exercise/ Number of voting % of
financial date[x] Conversion rights that may be voting
instrument Period[xi] acquired if the rights
instrument is
exercised/converted.

SUBTOTAL
8. B 1

B 2: Financial
Instruments
with similar
economic
effect
according to
Art. 13(1)(b)
of Directive
2004/109/EC
(DTR5.3.1.1
(b))
Type of Expiration Exercise/ Physical or Number of % of
financial date[x] Conversion cash voting voting
instrument Period settlement[xii] rights rights
[xi]

SUBTOTAL 8.B.2

[][][][]
9. Information in
relation to the
person subject to
the notification
obligation (please
mark the
applicable box
with an "X")
Person subject to
the notification
obligation is not
controlled by any
natural person or
legal entity and
does not control
any other
undertaking(s)
holding directly
or indirectly an
interest in the
(underlying)
issuer[xiii]
Full chain of X
controlled
undertakings
through which the
voting rights
and/or the
financial
instruments are
effectively held
starting with the
ultimate
controlling
natural person or
legal entity[xiv
](please add
additional rows as
necessary)
Name[xv] % of voting rights if it equals or is % of voting Total of
higher than the notifiable threshold rights both if it
through equals or
financial is higher
instruments than the
if it notifiable
equals or threshold
is higher
than the
notifiable
threshold
Timo Syrjälä 5.08% 5.08%
(Direct)
Acme Investments 9.02% 9.02%
SPF Sarl
(Indirect)

10. In case of
proxy voting,
please identify:
Name of the proxy
holder
The number and %
of voting rights
held
The date until
which the voting
rights will be
held

11. Additional
information[xvi]

Place of completion Luxembourg
Date of completion 10.05.2021

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage.